VERTEX PHARMACEUTICALS INC / MA

VRTX · CIK 0000875320

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$12.00B8.9%

FY2025

Net income (FY)

$3.95B838.1%

FY2025

Free cash flow (FY)

$3.19B504.1%

FY2025

Diluted EPS (FY)

$15.32836.5%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 68.4× since FY2008 · net margin -630.3% → 32.9%

MarginsNet marginFCF margin

FY2025: net 32.9% · free cash flow 26.6% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $3.63B operating cash − $437.6M capex = $3.19B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -59% (FY2009) → 21% (FY2025) · on assets 15.4%

Balance sheetLiabilitiesEquity

FY2025: $25.64B assets · $6.98B liabilities · $18.67B equity

The receipts

VERTEX PHARMACEUTICALS INC / MA

VRTX · CIK 0000875320

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$12.00B8.9%

FY2025

Net income (FY)

$3.95B838.1%

FY2025

Free cash flow (FY)

$3.19B504.1%

FY2025

Diluted EPS (FY)

$15.32836.5%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 68.4× since FY2008 · net margin -630.3% → 32.9%

MarginsNet marginFCF margin

FY2025: net 32.9% · free cash flow 26.6% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $3.63B operating cash − $437.6M capex = $3.19B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -59% (FY2009) → 21% (FY2025) · on assets 15.4%

Balance sheetLiabilitiesEquity

FY2025: $25.64B assets · $6.98B liabilities · $18.67B equity

The receipts